FATE: fatetherapeutics.com Price/Earnings to Growth Multiple
Fate Therapeutics, Inc. (FATE) is developing an advanced iPSC therapy system where cell safety is strictly regulated by the FDA. The company is designing the architecture of universal oncology drugs for mass production. The PEG ratio reflects the valuation dynamics, with the value of 0.00 serving as the current metric. Strategic alliances with pharma behemoths provide scientific synergy, as illustrated by this chart.
Analytical breakdowns for Fate Therapeutics, Inc. (FATE)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital Fate Therapeutics, Inc.|FATE - Long-Term Debt to Capital|Current Liabilities to Equity fatetherapeutics.com|FATE - Company Aggregate Debts|Debts to Book Capitalization Fate Therapeutics Corp|FATE - Company Long-Term Liabilities|Amount of Current Liabilities Fate Therapeutics|Immediate Liquidity fatetherapeutics.com
- company profitability and valuation multiples indicators:
FATE - Net Income|Expected Net Income Fate Therapeutics, Inc.|FATE - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Fate Pharma|FATE - PEG Multiple|Business Value to Operating Income Before Depreciation Fate Therapeutics Corp|FATE - Operating profit EBITDA|Net earnings per one share for the last twelve months Fate Therapeutics|FATE - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months fatetherapeutics.com|FATE - Earnings growth in current year|Earnings growth forecast for next year Fate Therapeutics, Inc.
General company analysis:FATE Fate Therapeutics Inc
The PEG ratio compares the current P/E multiple to the rate of earnings expansion, allowing for the determination of an asset's fair value relative to its growth dynamics. By analyzing this P/E-to-growth chart, an investor can identify business undervaluation, which is critically important for Fate Therapeutics, Inc. (FATE) during its period of clinical trials and the scaling of iPSC technologies to capture the oncology therapy market.
Who Fate Therapeutics, Inc. competes with
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|PEG Multiple DCTH|YMAB: Market Cap to Earnings and Growth Ratio|PEG Multiple AURA (Aura Biosciences)|PEG Multiple Candel Therapeutics Inc. CADL|ARAY: Price/Earnings to Growth Multiple|SELLAS Life Sciences - Company Value to Earnings Growth Ratio|ACTU: PEG Multiple|Price to Earnings Adjusted for Growth Rate citiusonc.com (CTOR)|Price/Earnings to Growth Multiple HURA|TARA: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple WHWK (Aadi Bioscience Inc)|Company Value to Earnings Growth Ratio TCRX|PEG Multiple CSBR (Champions Oncology, Inc.)|Growth-Adjusted Payback Ratio XBIT|CEL-SCI Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate OS Therapies Inc.|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|Artiva Biotherapeutics - Growth-Adjusted Payback Ratio|ANL (Adlai Nortye Ltd) - PEG Multiple|PEG Multiple verupharma.com|Price/Earnings to Growth Ratio Tempest Therapeutics, Inc. (TPST)|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro)|Mural Oncology PLC (MURA) - Price to Earnings Adjusted for Growth Rate|KAPA: Price/Earnings to Growth Multiple|OKUR - PEG Multiple|GDTC (w2.cytomed.sg) - Price/Earnings to Growth Multiple|CRIS: Company Value to Earnings Growth Ratio|APLM (Apollomics Inc.) - PEG Multiple|Tharimmune Corporation (THAR) - Growth-Adjusted Market Cap to Net Income|PEG Multiple ADVB|Price/Earnings to Growth Multiple genprex.com GNPX|Price/Earnings to Growth Ratio Calidi Biotherapeutics, Inc. CLDI|Growth-Adjusted Market Cap to Net Income Sunshine Biopharma Inc. (SBFM)|XBIO: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio SLRX (Salarius Pharma)|PPBT: PEG Multiple|AONC - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio BeiGene|Growth-Adjusted P/E Ratio CKPT (Checkpoint Therapeutics Inc.)|PEG Multiple ELEV|Price/Earnings to Growth Multiple icadmed.com ICAD|Ikena Oncology - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income notablelabs.com (NTBL)|Viracta - PEG Multiple|Market Cap to Earnings and Growth Ratio MOR|NAYA: PEG Multiple|Ascentage (AAPGV) - PEG Multiple
